Novartis’s Fevipiprant Hit By Phase III Asthma Failure
ZEAL Studies Miss Efficacy In Moderate Disease
Executive Summary
Novartis’s investigational oral therapy for asthma fell at the first Phase III hurdle but pivotal studies in severe disease will be key to prospects.
You may also be interested in...
Novartis's Zolgensma Finds Commercial Legs In A First For Gene Therapy
Zolgensma generated $160m in the third quarter, a strong launch for the gene therapy's first full quarter on the market.
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.